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Abstract
The occurrence of Graft-versus-Host Disease (GvHD) is a prevalent and potentially lethal complication that develops
following hematopoietic stem cell transplantation. Humanized mouse models of xenogeneic-GvHD based upon
immunodeficient strains injected with human peripheral blood mononuclear cells (PBMC; ‘‘Hu-PBMC mice’’) are important
tools to study human immune function in vivo. The recent introduction of targeted deletions at the interleukin-2 common
gamma chain (IL-2Rcnull), notably the NOD-scid IL-2Rcnull (NSG) and BALB/c-Rag2null IL-2Rcnull (BRG) mice, has led to
improved human cell engraftment. Despite their widespread use, a comprehensive characterisation of engraftment and
GvHD development in the Hu-PBMC NSG and BRG models has never been performed in parallel. We compared engrafted
human lymphocyte populations in the peripheral blood, spleens, lymph nodes and bone marrow of these mice. Kinetics of
engraftment differed between the two strains, in particular a significantly faster expansion of the human CD45+
compartment and higher engraftment levels of CD3+ T-cells were observed in NSG mice, which may explain the faster rate
of GvHD development in this model. The pathogenesis of human GvHD involves anti-host effector cell reactivity and
cutaneous tissue infiltration. Despite this, the presence of T-cell subsets and tissue homing markers has only recently been
characterised in the peripheral blood of patients and has never been properly defined in Hu-PBMC models of GvHD.
Engrafted human cells in NSG mice shows a prevalence of tissue homing cells with a T-effector memory (TEM) phenotype
and high levels of cutaneous lymphocyte antigen (CLA) expression. Characterization of Hu-PBMC mice provides a strong
preclinical platform for the application of novel immunotherapies targeting TEM-cell driven GvHD.
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Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) can
be a potential curative therapy for a variety of malignant and non-
malignant hematological diseases. While beneficial graft-versus-
tumour immune responses are elicited by transferred donor
derived T-cells, the alloreactivity of these cells against HLA
disparities and minor antigens can result in the initiation of graft-
versus-host disease (GvHD). The development of GvHD is a
potentially life threatening complication that often commences
with an acute phase–with surviving patients then being affected by
the chronic form of the disease [1]. Lymphocyte depletion is used
to reduce the GvHD alloresponse [2,3] but this non-specific
approach leaves patients at considerable risk of complications such
as infection or cancer relapse. Therefore, better intervention
therapies to prevent GvHD are required.
The generation of immunodeficient mice bearing a targeted
mutation in the IL-2 receptor common gamma chain (IL-2Rcnull),
notably the NOD-scid IL-2Rcnull (abbreviated NSG) and BALB/c-
Rag2null IL-2Rcnull (abbreviated BRG) that lack T- B- and NK-
cells, permits acceptance of human cells and tissues [4,5]. These
strains engraft readily following intravenous injection of human
peripheral blood mononuclear cells (PBMCs; abbreviated as Hu-
PBMC mice). Hu-PBMC NSG and Hu-PBMC BRG mice are
currently used as reliable models of human-into-mouse xenogeneic
GvHD where the engrafted cells are amenable to regulation by
therapeutic agents or adoptively transferred human immune cells
such as regulatory T-cells (Tregs) or tolerogenic dendritic cells [6–
12]. These mice are therefore useful models for pre-clinical
evaluation of novel GvHD therapies. GvHD development in these
models is dependent upon human PBMC xeno-reactivity with
foreign host major histocompatibility (MHC) class I and class II
[11], resembling HLA mismatched HSCT in clinical GvHD
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where donor cell alloreactivity is initiated by recognition of foreign
MHC antigens expressed by recipient cells [13]. In human acute
GvHD, the characteristic involvement of specific organs strongly
suggests that immune cell trafficking is essential to the pathophys-
iology of disease. This has been linked to the expression of homing
receptors that direct T-cells to specific extralymphoid tissues.
Recent reports have pointed towards alterations of T-cell
expression of the specific skin homing marker cutaneous lympho-
cyte antigen (CLA) as a predictive immunobiological marker of
acute GvHD in the periphery of HSCT patients [14,15]. Such
human studies employ analysis of peripheral blood because patient
tissues are usually inaccessible due to obvious ethical and technical
constraints. The opportunity to examine via flow cytometry the T-
cell composition and reconstitution of lymphoid organs in GvHD
patients is crucial for developing preventative strategies.
In this work, we describe the first systematic comparative
characterization of tissue lymphocyte populations and kinetics
between Hu-PBMC NSG and BRG mice, the two most widely
used immunodeficient strains to study xenogeneic GvHD. The
major aim of our study was to firstly determine the differential rate
of GvHD development, which is a critical factor to consider when
selecting a model to assess the efficacy of novel immunotherapies
rapidly. These data show that NSG mice are more optimal and
robust models of GvHD with a significantly faster rate of disease
development. We then chose Hu-PBMC NSG mice to perform
extensive tissue phenotyping of naive and memory T-cell subsets
and CLA expression, which has not been properly defined in these
humanized mice. The characterization of engrafted cells in these
Hu-PBMC models can be used as pre-clinical platforms to develop
novel therapeutic strategies for clinical application.
Materials and Methods
Ethics Statement
This study involving the use of human participants was
specifically approved by the institutional review board of Guy’s
Hospital (Guy’s Research Ethics Committee, Ethics Committee
Code: 06/Q0704/18) and conducted in accordance with the
Helsinki Declaration. Informed written consent was obtained from
all healthy controls prior to enrolment into the study. Animals
were maintained under specific pathogen-free conditions and all
animal experiments were specifically approved by the Institutional
Committees on Animal Welfare of the United Kingdom Home
Office (the Home Office Animals Scientific Procedures Act, 1986).
Immunodeficient Mice
Male and female NOD/scid/IL-2Rc2/2 mice (NOD.cg-
PrkdcscidIl2rgtm1Wjl/SzJ abbreviated to NSG; obtained from The
Jackson Laboratory) and BALB/c RAG22/2cc
2/2 mice (abbre-
viated to BRG; kindly provided by Prof. Adrian Hayday, The
London Research Institute, Cancer Research UK, London,
England, UK; and P. Gorer, Department of Immunobiology,
King’s College School of Medicine at Guy’s Hospital, London,
England, UK) were used between 6–12 weeks of age.
Histological analysis of mouse skin
Mouse skin was harvested and snap frozen in optimum cutting
temperature (OCT) solution over pre-cooled isopentane. Frozen
blocks were then cut at 6–8 mm and stored at 280uC until use.
Sections were air dried, fixed in cold acetone. Non-specific Fc
receptor binding was measured using isotype non-binding control
antibodies. Immunohistochemical staining was performed using
an avidin-biotin methodology with mouse monoclonal antibodies
specific for human CD45 (clone HI30; eBioscience). Dilutions
were conducted as per manufacturer’s guidance. An appropriate
biotinylated secondary antibody was then added at a 1:200 dilution
and left for 60 min at room temperature. Sections were treated with
the ABC Vectastain Elite kit (VectorLabs, Peterborough UK) and
the colour developed using 3-diaminobenzidine then counterstained
with hematoxylin for visualisation by light microscopy.
Humanised mouse model of xeno-Graft-versus-Host
Disease (GvHD)
PBMCs were isolated from buffy coats (provided by the
National Blood Transfusion Centre; South Thames, Tooting,
UK), by density gradient centrifugation over Lymphocyte
Separation Medium (PAA), and then resuspended in 200 ml of
PBS in insulin syringes (VWR). Xenogeneic GvHD was induced
by intravenous injection of 107 human PBMCs via the tail vein
into unconditioned adult NSG and BRG mice. In the lightly
irradiated xeno-GvHD model, NSG mice were first irradiated
with 2.4 Gy and injected 24 hours later with human PBMCs. In
all experiments, fresh human PBMC were used and were never
freeze-thawed. Animals that developed clinical symptoms of
Figure 1. NSG mice develop GvHD at a faster rate than BRG
mice. 107 freshly isolated human PBMCs were injected intravenously
via the tail vein into adult 6–10 week old NSG and BRG immunode-
ficient mice. (A) Survival of NSG mice [median survival time (MST) = 40
days, n= 12, 4 PBMC donors] was significantly shorter than that of BRG
mice (MST = 71, n= 10, 3 PBMC donors). (B) The average weight is
shown as a percentage of starting weight. (A) Log-rank Mantel-Cox Test
and (B) unpaired t test. Each data point represents the mean 6SEM.
doi:10.1371/journal.pone.0044219.g001
Xeno Graft-versus-Host-Disease in IL-2Rcnull Mice
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GvHD (.15% weight loss, hunched posture, fur loss, reduced
mobility, tachypnea) were sacrificed and an end point of survival
was recorded for all Hu-PBMC mice.
Antibodies and flow cytometry
The following antibodies were used in dilutions according to
manufacturers instructions: FITC conjugated anti-human CD62L
(Invitrogen), PE conjugated anti-human CD27 (eBioscience), PE
conjugated anti-human CD25 (BD), PE conjugated anti-human
CLA (Miltenyi), PE-Cy5.5 conjugated anti-human CD3 (Invitro-
gen), PE-Cy5.5 conjugated anti-human CD20 (Invitrogen), PE-
Cy7 conjugated anti-mouse CD45 (eBioscience), PE-TR conju-
gated anti-human CD4 (Invitrogen), APC conjugated anti-human
CD8 (Invitrogen), APC-Cy7 conjugated anti-human CD45
(eBioscience), and Pacific Blue conjugated anti-human CD45RO
(BD). Single-cell suspensions from spleens, bone marrows and
lymph nodes were prepared in PBS containing 1% fetal bovine
serum (Sigma) and 2 mM EDTA (Invitrogen). Blood was collected
via tail vein bleeding using EDTA-coated capillary tubes.
CountBright absolute counting beads (Invitrogen) were added to
spleen samples prior to acquisition and absolute numbers of cells
calculated accordingly.
Lymph nodes in NSG and BRG mice are highly atrophic,
however during xeno-GvHD progression distinct lymph
node structures become apparent in the axial and
brachial positions that were harvested and pooled for
cellular analysis
Single cell suspensions were incubated in anti-mouse CD16/32
(clone 2.4G2; BD) for 5 min at 4uC to block nonspecific Fc
Figure 2. Kinetics of human cell engraftment in NSG and BRG mice. Peripheral blood was collected from Hu-PBMC mice bi-weekly and
stained with anti-human specific antibodies for human (A) CD45, (B) CD3, (C) CD20, (D) CD25, and (E) CD45RO and quantified by flow cytometry. 2-
way ANOVA test was performed. Each data point represents the average (n= 4 NSG and BRG mice respectively, 2 PBMC donors) 6SEM values.
doi:10.1371/journal.pone.0044219.g002
Xeno Graft-versus-Host-Disease in IL-2Rcnull Mice
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binding and antibodies were then added in the appropriate
combinations. Labeled cells were washed, and at least 100,000
events were acquired were acquired with a BD FACS Canto (BD)
and data were analyzed by FlowJo (TreeStar) software. For all
analyses, anti-mouse CD45 staining was performed to exclude
murine host cells from analysis, and only those cells that were
human CD45 positive and mouse CD45 negative were included in
the final calculation of reported values [16]. CD3+ CD4+ and
CD3+ CD8+ T-cell subsets were defined as CD45RO2CD27+
naı¨ve, CD45RO+ CD27+ CD62L+ central memory, CD45RO+
CD27+ CD62L2 effector memory, CD45RO+ CD272 effectors
and CD45RO2 CD272 terminal effectors (please see Supple-
mentary Figure 1 for representative gating strategies).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
version 4.0 (GraphPad Software). All measures of variance are
presented as standard error of the mean (SEM). Results were
assessed for normal Gaussian distribution and then analyzed by
Mann-Whitney non-parametric t test, one-way ANOVA test, two-
way ANOVA, or Mantel-Cox as indicated. Data were considered
to be significantly different when P,0.05, P,0.01, or P,0.001
represented in the figures and tables as *, **, or ***, respectively.
Results
Engraftment kinetics of human cells in Hu-PBMC NSG
and BRG mice
Several reports have shown that NSG and BRG mice engraft
efficiently with human PBMC in the absence of host pre-
conditioning [6,11,17–19], but a systematic comparison between
the two strains has never been performed. To this end, NSG and
BRG mice at 6–12 weeks of age were injected intravenously with
107 human PBMC via the tail vein. Both strains developed GvHD
consistently with accelerated weight loss and significantly faster
disease development in NSG mice [median survival time
(MST) = 40 days vs. 71 days in Hu-PBMC BRG mice; P,0.001;
Fig. 1A–B]. Kinetics of human cell engraftment in the peripheral
blood was evaluated bi-weekly until mice developed GvHD. At
which point, spleens, lymph nodes, and bone marrow were also
harvested for analysis. Levels of human CD45+ cells in the
periphery of NSG mice at three and five weeks post injection were
significantly higher than those achieved in BRG mice (P,0.01),
where expansion was much slower (Fig. 2A). In agreement with
previous studies [18], the majority of the engrafted cells in NSG
mice were CD3+ (.95%; Fig. 2B), whereas in BRG mice these
proportions were significantly lower (,80%) at early time points
(P,0.01; Fig. 2B).
Figure 3. Kinetics of splenic lymphocyte engraftment in Hu-PBMC NSG and BRG mice. Cells were harvested from the spleens of Hu-PBMC
NSG and BRG mice at weekly intervals following transfer and stained with anti-human specific antibodies for mouse CD45 and for human CD45, CD3,
CD4, and CD20. Samples were analysed by flow cytometry to calculate the % of human (A) CD45+, (C) CD3+ and (G) CD20+, the absolute accumulation
of human (B) CD45+, (D) CD3+, (E) CD8+, (F) CD4+ and (H) CD20+ cells. 2-way ANOVA test was performed. Data are compiled from 2 independent
experiments (NSG n = 4–5 per time point and BRG n = 4 day 7–21 or n = 2 day 28, 2 PBMC donors).
doi:10.1371/journal.pone.0044219.g003
Figure 4. Human lymphocyte populations from Hu-PBMC NSG and BRG mice tissues harvested at xenogeneic Graft-versus-Host-
Disease (GvHD). Peripheral blood, spleen, lymph nodes, and bone marrow were harvested at GvHD development in Hu-PBMC NSG and BRG mice
and stained with anti-human specific antibodies for human (A) CD45, (B) CD3, (C) CD4, (D) CD25, (E) CD45RO, and (F) CD20 and quantified by flow
cytometry. Tukey box-and-whisker graphs are shown. Unpaired t test was performed. Data are compiled from 3 independent experiments (n= 4 NSG
and BRG mice respectively, 2 PBMC donors).
doi:10.1371/journal.pone.0044219.g004
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To confirm the difference in human cell expansion in the
periphery of the two strains, we then performed kinetic analysis of
chimaerism in the spleen during the first four weeks of human
PBMC engraftment. Indeed, very much mirroring peripheral
blood reconstitution in these mice, there was a significantly higher
proportion of human CD45+ cells in NSG mice as compared to
BRG mice at all four weekly time points measured post PBMC
transfer (Fig. 3A). The overall cellularity of the spleens was also
greatly increased (Fig. 3B) mainly as a result of a dramatic
accumulation of donor T-cells (Fig. 3C and D). CD4 and CD8 T-
cell subsets accumulated in both NSG and BRG mice but with
significantly greater accumulation in NSG mice (Fig. 3E and F).
The proportion of CD20+ B-cells contracted with time, reflecting
the huge expansion in T-cells, (Fig 3G) however, the absolute
number of B-cells increased during the 4-week time course. Once
again the absolute splenic accumulation of B-cells was greater in
NSG mice than in BRG recipients.
Previous studies have shown that the majority of engrafted
human cells in immunodeficient mice (including NSG mice)
develop an activated/memory CD45RO+ phenotype [18,20]. We
decided to monitor CD45RO, and an additional activation
marker CD25, in the peripheral blood (Fig. 2D–E) and in the
tissues (Fig. 4D–E) of Hu-PBMC NSG and BRG mice. CD45RO
expression was consistent between the two strains, however,
expression of CD25 on donor T-cells was significantly different in
the blood at 5 weeks and in all tissues upon harvest, with .90% of
T-cells in NSG mice expressing CD25 (Fig. 2D and 4E), this may
reflect host-dependent differences in the degree or kinetics of T-
cell activation. T-cell expression of CD69 was also measured and
found to be similar at all time points (data not shown).
Upon harvest no differences were detected in the proportion of
CD3+ T-cells in lymphoid tissues (Fig. 4B). One notable disparity
between the two models was a significantly higher proportion of
CD20+ B-cells in the lymph nodes (P,0.001) and bone marrow
(P,0.01) of NSG mice (Fig. 4F).
Overall, these data show that NSG mice develop GvHD
significantly faster than BRG mice, an important factor consid-
ering the use of these models as rapid tools for the assessment of
novel therapeutics. We therefore selected the Hu-PBMC NSG
model for all subsequent characterization.
Figure 5. Sublethal irradiation accelerates xenogeneic Graft-versus-Host-Disease (GvHD) in Hu-PBMC NSG mice. 107 freshly isolated
PBMCs were injected intravenously via the tail vein into adult 6–12 week old NSG immunodeficient mice 24 hours post sub lethal irradiation (2.4 Gys).
(A) Survival of irradiated Hu-PBMC NSG mice (MST = 14 days, n= 7, 2 PBMC donors). (B) The average weight is shown as a percentage of starting
weight. Peripheral blood, spleen and bone marrow were harvested from irradiated Hu-PBMC NSG mice at the indicated time points and analysed for
(C) human CD45 engraftment and (D) CD4:CD8 ratio. Black bar represents human PBMC phenotype pre-injection. Data represent the mean
6SEM and are compiled from 2 independent experiments (n = 7). (A) Log-rank Mantel-Cox Test, (B, D) unpaired t test, and (C) 2-way ANOVA, spleen vs
blood (*,**) and spleen vs bone marrow (##).
doi:10.1371/journal.pone.0044219.g005
Xeno Graft-versus-Host-Disease in IL-2Rcnull Mice
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Tissues from Hu-PBMC NSG mice display a T-effector
memory (TEM) phenotype
Although Hu-PBMC NSG mice show gradual weight loss and
eventual GvHD over a 50 day period (Fig. 1A and B), we decided
to accelerate disease development by introducing a protocol of
light irradiation prior to adoptive transfer of human cells [11]
(Fig. 5A–B; MST = 14 days vs. 40 days in unconditioned Hu-
PBMC NSG mice). This allowed us to study an even more
optimized GvHD model, where disease development is signifi-
cantly more rapid. We firstly examined the kinetics of human cell
engraftment in tissues of irradiated Hu-PBMC NSG mice. Human
CD45+ engraftment levels were significantly higher in the spleen at
day 7 (P,0.01 vs blood and bone marrow) and day 15 (P,0.05 vs
blood and P,0.01 vs bone marrow) but was then equal at day 27
(Fig. 5C). Comparison of the CD4:CD8 compartment within this
human CD45+ population between early (day 7) and late (GvHD)
time points revealed a significantly reduced ratio in all tissues
examined (Fig. 5D). We have observed previously in patients with
GvHD that phenotypic characterization of naı¨ve, memory, and
effector T-cell subsets can reveal important insights into the
immunological basis of disease [21]. To determine the presence
and/or proportions of T-cell subsets in Hu-PBMC NSG mice is
important to understand the type of immune response that is
associated with xeno-GvHD pathology in these humanized
models. CD45RO, CD27, and CD62L were combined with
anti-CD4 and anti-CD8 antibodies to analyze within the CD4+
and CD8+ populations the effectors (CD45RO+CD272), the naı¨ve
(CD45RO2CD27+) to memory (CD45RO+CD27+) ratio, and the
TCM (CD45RO
+CD27+CD62L+) to TEM (CD45RO
+CD27+
CD62L2) ratio. Representative examples of gating strategies used
to define T-cell subsets in mouse tissues are shown in Fig. S1.
While there were no differences in the proportion of effector
CD4+ T-cells present in the tissues (Fig. 6A), this was significantly
reduced in the CD8+ T-cell pool at harvest after GvHD
development (Fig. 6D). However, for both lineages the naı¨ve:-
memory ratio was significantly lower at harvest as compared to
day 7 (Fig. 6B and E). To further investigate this increased
percentage of memory T-cells, we subdivided these into TCM and
TEM to compare relative differences. Phenotypic analysis showed a
markedly reduced TCM:TEM ratio within the CD4
+ fraction in all
tissues analysed (Fig. 6C). This was also true for the CD8+ fraction
in the peripheral blood and spleen (Fig. 6F). The increasing
proportion of T-cells with an effector memory phenotype in Hu-
PBMC NSG mice at GvHD development potentially suggests
xenoantigen-driven survival and expansion. Interestingly, the ratio
of TCM:TEM cells remains high in the lymphoid organs suggesting
that central memory cells in these organs may act as a reservoir for
the expansion of effector memory cells in the blood.
Engrafted T-cells express cutaneous lymphocyte antigen
(CLA) and home to murine skin
In human-into-mouse xenogeneic GvHD there have been
reports of human immune cell infiltration into peripheral tissues
such as the skin [6,11,22–24], mimicking the human form of the
disease [25]. In some mice, we also observed signs of cutaneous
GvHD pathology that manifested mainly as hair loss (data not
shown). We therefore hypothesized that T-cell expression of CLA,
which mediates specific skin homing of circulating peripheral
blood T-cells [26–29], may increase during the course of GvHD in
Hu-PBMC NSG mice. Indeed, in the peripheral circulation (but
Figure 6. Engrafted T-cells in Hu-PBMC NSG mice display an effector memory tissue homing phenotype. Tissues were harvested from
irradiated Hu-PBMC NSG mice at the indicated time points and T-cell subset compositions quantified: (A and D) CD45RO+CD272 effectors, (B and E)
naı¨ve (CD45RO2CD27+) to memory (CD45RO+CD27+) ratio, and (C and F) central memory (CD45RO+CD27+CD62L+) to effector memory
(CD45RO+CD27+CD62L2) ratio. Black bars represent human PBMC phenotype pre-injection. Unpaired t test was performed. Each data point
represents the mean 6SEM and are compiled from 2 independent experiments (n= 7).
doi:10.1371/journal.pone.0044219.g006
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not in the spleens or bone marrow) there was significantly higher
CLA expression among CD3+ T-cells at the point of GvHD
development (P,0.01; Fig. 7B). To further characterise this
expression, we analysed the composition of CLA expressing CD3+
T-cells and observed a decreased CD4:CD8 ratio, that again only
reached statistical significance in the peripheral circulation
(P,0.05; Fig. 7C). In addition, the skin homing chemokine
receptors CCR4 and CCR6 [30] were also expressed on T-cells of
Hu-PBMC NSG mice (Fig. S2A and B), further supporting our
hypothesis. We then performed immunohistochemical staining of
CD45+ cells in murine skin (Fig. S2C) showing that these engrafted
human cells can infiltrate into the dermis (also confirming previous
reports showing mouse skin infiltration in this model [11]).
Discussion
Immunodeficient mice with the targeted IL-2Rcnull mutation,
namely the NSG and BRG, are rapidly becoming the superior
choice of host for the creation of ‘‘Human Immune System’’ mice
via reconstitution with human hematopoietic stem cells [4,5].
These strains also support high levels of human PBMC
engraftment without the requirement of pre-conditioning regimens
such as total body irradiation or depletion of host macrophages,
that were pre-requisites for successful engraftment in previous
generations of immunodeficient mice [6,11,17–19]. In this study,
we have performed the first comparative phenotypic character-
ization of human PBMC engraftment and kinetics in the two most
commonly used mouse models of xenogeneic GvHD, Hu-PBMC
NSG and BRG mice.
Human PBMCs from the same donors induced GvHD in both
strains consistently, however at different rates. NSG mice are
superior models in this respect as they develop GvHD significantly
faster than BRG mice. Investigating the kinetics of human cell
engraftment revealed that while human CD45+ levels increased in
the peripheral circulation of both strains, this was significantly
higher in NSG hosts. Furthermore, the expansion of the human
compartment was also significantly faster in NSG mice as levels of
human CD45 were .40% at five weeks post transfer of PBMC, at
which point BRG mice only harboured ,10%. It has previously
been suggested that the development of xenogeneic GvHD in
lymhodepleted hosts is driven by recognition of host MHC and is
therefore dependant upon relatively high levels of T-cell engraft-
ment [31]. Evaluation of T-cell kinetics indicated relatively lower
proportions and of CD3+ cells in the periphery and spleens of
BRG mice early time points post adoptive transfer of human cells.
These data potentially suggest that the delayed time for GvHD
Figure 7. Human T-cells in Hu-PBMC NSG mice display skin homing capabilities. Peripheral blood, spleen and bone marrow were
harvested from irradiated Hu-PBMC NSG mice at the indicated time points. Representative gating of peripheral blood is shown in (A). CD3+ T-cells
were analysed for (B) CLA expression and (C) CD4 to CD8 ratio of CLA expressing CD3+ T-cells. Black bars represent human PBMC phenotype
pre-injection. Unpaired t test was performed. Each data point represents the mean 6SEM and are compiled from 2 independent experiments
(n= 7).
doi:10.1371/journal.pone.0044219.g007
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development in the Hu-PBMC BRG model may be attributed to
differences in the kinetics of human cell expansion and overall
differential proportion of CD3+ T-cell engraftment.
T-cells of the CD4 and/or CD8 lineage are principle effectors of
the immune response [2,3], however the heterogeneity of the T-
cell pool is scarcely taken into account in human GvHD studies.
T-cells may be broadly divided into those that are antigen-
inexperienced (naive T-cells) and antigen-experienced (which
include effector and memory T-cells) [32,33]. Memory T-cells
can be further subdivided into effector memory T-cells (TEM) that
preferentially migrate to inflamed peripheral tissues and are the
major effector arm. Most cases of human acute GvHD begin with
cutaneous lesions that often appear 2–3 weeks post HSCT, which
result from the immune reactivity and homing of transplanted cells
to target organs [25]. Conversely, central memory T-cells (TCM)
efficiently home to secondary lymphoid organs and have little to
no effector activity [34]. We have recently performed a
longitudinal analysis of lymphocyte subset reconstitution in the
peripheral blood of patients undergoing HSCT, showing that an
imbalance of effector and regulatory T-cells is an indicative
signature of GvHD in the context of T-cell depletion with
campath 1H and cyclosporine prophylaxis [21]. Furthermore, in
patients that develop acute GvHD, higher numbers of peripheral
effector and effector memory CD4+ T-cells were prevalent. This
‘signature’ of GvHD is specific to a particular HSCT treatment
regimen, as other treatments have been shown to lead to distinct
pathways of pathology (as shown in [2] and [3] where CD8+ T-
cells are essential). It seems that virtually any T-cell subset can
potentially contribute to GVHD since the type of immune
response that dominated probably depends on ‘environment’.
Zheng et al.,[35] have shown that CD8+ TCM cells are capable of
inducing GvHD whereas other studies have shown a relative
inability of memory T-cells to cause GvHD [36]. Indeed, in our
lightly irradiated Hu-PBMC NSG model, we observed an increase
of engrafted human cells with a TEM tissue homing phenotype,
both within the CD4 and CD8 lineages. Despite a reduction in the
CD8+ TCM to TEM ratio we observed large proportions of these
cells still present upon harvest (,40:1), suggesting that CD8+ TCM
cells may also be involved in xeno-GvHD response in this model.
Concomitant with an enlarged presence of TEM cells was an
increased proportion of CLA+ T-cells present in the peripheral
circulation, that were capable of homing to murine skin. A major
aim of our study was to identify an optimal strain for the study of
xenogeneic GvHD, and we selected the NSG mice to further
characterize as disease onset was more rapid in this strain and
displayed increased levels of human cell expansion as compared to
BRG mice. Although we focused on characterizing T-cell subsets
in irradiated Hu-PBMC NSG mice, it would also be interesting
and informative to study the effect of irradiation pre-conditioning
in BRG mice. Given the rapid development of disease and higher
T-cell engraftment, NSG mice would be the strain of choice for
most researchers studying T-cell driven xeno-GvHD in human
PBMC engrafted mice.
In conclusion, our study has characterized T-cell subsets
involved in the xeno-immune response of Hu-PBMC NSG and
BRG mice. We decided to focus on defining the nature of the T-
cell response associated with xeno-GvHD pathology in these
humanized mice and show that Hu-PBMC NSG mice display a
prevalence of tissue homing TEM cells. Overall, illustrating that
there are sufficient similarities between these models and what is
known to occur in the clinical HSCT setting. These small animal
models that can mimic certain aspects of clinical GvHD will
therefore be useful for evaluating control of human TEM-cell
driven GvHD by novel interventional therapies.
Supporting Information
Figure S1 Representative gating strategies to identify
memory T-cells in human PBMCs and Hu-PBMC NSG
mice. Within the human CD45+ mouse CD452 human CD3+
gate, CD4+ and CD8+ cells (top panel in A and B) were then selected
to analyze CD4+ T-cell subsets (middle panel in blue box) and CD8+
T-cell subsets (bottom panel in red box). Subset classifications were
as follows; effectors: CD45RO+CD272; naı¨ve: CD45RO2CD27+;
and memory: CD45RO+CD27+. The memory population was then
further subdivided into central memory: CD45RO+CD27+CD62L+
and effector memory: CD45RO+CD27+CD62L2.
(TIF)
Figure S2 Human T-cells in Hu-PBMC NSG mice
express skin homing chemokine receptors. Peripheral
blood, spleen and bone marrow were harvested from irradiated
Hu-PBMC NSG mice at the indicated time points and CD3+ T-
cells were analysed for (A) CCR4 and (B) CCR6 expression among
engrafted CD3+ T-cells. (C) Human CD45+ cells were detected via
immunohistochemical staining of mouse skin from irradiated Hu-
PBMC NSG mice. Black bars represent human PBMC
phenotype pre-injection. Unpaired t test was performed for
each tissue that showed no statistically significant differences. Each
data point represents the mean 6SEM and are compiled from 2
independent experiments (n = 7).
(TIF)
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